Cover Image: February 2008 Scientific American Magazine See Inside

Letters

Drug Access -- Conservation Strategy -- Consciousness















Share on Tumblr

All this suggests a rather high degree of consciousness and awareness of one’s surroundings while sleeping.

Garry Wainscott
Perth, Australia

Blastoff Bias?
“To the Moon and Beyond,” by Charles Dingell, William A. Johns and Julie Kramer White, posits NASA’s Orion space vehicle as a possible basis for a manned craft capable of traveling to Mars. The authors are all employees of NASA or Lockheed Martin (the lead contractor on the project), and this article represents a disturbing trend of presenting press releases or puff pieces as articles with journalistic integrity. A serious article on this project could have been written by a real science journalist, who would have weighed the claims of the NASA staff.

Gil Hennessey
New York City

The Hard Stuff
In “The Really Hard Science”, Michael Shermer laments the practice of labeling different fields of science as “hard” or “soft,” with “hard” sciences respected as being more “difficult.” This view is one I had not considered. I always saw physics and math as “hard,” not because they are considered more difficult but because they can be somewhat constrained. The “soft” sciences are less possible to constrain—their “laws” are more subject to interpretation and harder to confirm experimentally. Computing a planetary orbit can be carried to many decimal places with accuracy. Determining the level of anger in a given population can only be computed with statistical uncertainty. The latter is probably more difficult and the former more reliable.

Richard Podraza
via e-mail



Subscribe     Buy This Issue

Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.

1 Comments

Add Comment
View
  1. 1. Go Yoshida 03:41 PM 3/9/08

    To be sure there is a dilemma of whether to permit earlier-stage patients, who have more established treatment options, to use an experimetal drugs or therapy for clinical trial, difficult-to-treat patients have resistance even to standard therapy.
    That is why patients with malignancy are not good for clinical trials.
    In any way, physicians have to keep in mind not to cause selection bias when analyzing the outcome of clinical trials.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

Tweets could not be retrieved at this time

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Email this Article

Letters: Scientific American Magazine

X
Scientific American MIND iPad

Tap into your MIND

Get Both Print & Tablet Editions for one low price!

Subscribe Now >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X